Not for publication or distribution in the United States, Canada, Australia or Japan.
MEDIAN Technologies (ALMDT.PA), a leading medical imaging solution provider, announced in a press release dated July 3rd, 2015, that it has obtained commitments from seven foreign institutional investors led by Abingworth, to subscribe to a new financing. Four of the participants in the transaction were existing shareholders in the Company. The financing amounted to €19.8 million in a private placement with institutional investors from the sale of 1,650,000 new shares of its common stock at a price of €12.00 per share, with a share premium of €11.95.
After completion of this transaction, the share capital of MEDIAN Technologies will be composed of 9,911,092 shares representing 9,906,671 voting rights.
Today, MEDIAN Technologies announces the final realization of this share capital increase of €19.8 million.
It is recalled that the newly issued shares will be added to the 8,256,671 MEDIAN Technologies’ currently outstanding shares, and will represent 19.97% of the share capital of MEDIAN Technologies, reflecting a dilution of 16.65% for the existing shareholders.
The shares will be listed on the Alternext Market of Euronext Paris on the same listing line of the existing shares under ISIN Code: FR0011049824. Payment and delivery of the shares will be made on July 17th, 2015.
Trading of MEDIAN Technologies shares which were suspended on July 3rd, 2015 for the purpose of this share capital increase, will resume tomorrow, on July 16th, 2015.
Cowen and Company served as placement agent to the Company.
The original version of this press release is the French version. This version is a translation and should in no way be considered official. The original French version shall prevail over this translation in English. The translation must always be construed according to the original version in French.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.